Keywords: glivec, shows, promise, stromal, tumors, novartis, chronic

Glivec shows promise in stromal tumors

Article | 06 April 2001

Print This

Novartis' chronic myeloid leukemia drug Glivec (imatinib mesylate),which is currently under fast-track review in the USA and the European ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in